Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

NCT05117138 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.

NCT NCT05117138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
Lead sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
March 1, 2024
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer